LEADER 04942nam 2200661 450 001 9910827088603321 005 20230801232320.0 010 $a0-567-01900-4 035 $a(CKB)3230000000205248 035 $a(EBL)1749976 035 $a(OCoLC)893331272 035 $a(SSID)ssj0001196983 035 $a(PQKBManifestationID)12463008 035 $a(PQKBTitleCode)TC0001196983 035 $a(PQKBWorkID)11184548 035 $a(PQKB)10113302 035 $a(MiAaPQ)EBC1749976 035 $a(Au-PeEL)EBL1749976 035 $a(CaPaEBR)ebr10869605 035 $a(CaONFJC)MIL615508 035 $a(EXLCZ)993230000000205248 100 $a20140523h20122012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aNew Testament theology in a secular world $ea constructivist work in philosophical epistemology and Christian apologetics /$fPeter Lampe ; translated by Robert L. Brawley from the German edition, with substantial subsequent revisions and augmentations by the author 210 1$aLondon ;$aNew York, New York :$cT & T Clark,$d2012. 210 4$dİ2012 215 $a1 online resource (226 p.) 300 $a"Translated from the German edition, Die Wirklichkeit als Bild: das Neue Testament als ein Grunddokument abendla?ndischer Kultur im Lichte konstruktivistischer Epistemologie und Wissenssoziologie, with substantial subsequent revisions and augmentations by the author"--T.p. verso. 300 $a"A Continuum imprint"--T.p. verso. 311 $a0-567-32417-6 320 $aIncludes bibliographical references and indexes. 327 $a""Contents""; ""Abbreviations""; ""Chapter I Introduction:Indicating the Problem""; ""Chapter II Stages in the History of Thought on the Way toConstructivism""; ""1 Between Naive Realism and Ontological Idealism""; ""2 On the Concept of Truth""; ""Chapter III The Brain as a Designer""; ""1 Neurophysiological Reasons for Constructivism""; ""2 Does an External Ontic Reality Exist?""; ""3 The a???Othera???, the a???Selfa???, and the Freedom of the Will asRealities Constructed by the Brain?""; ""4 Gaps between Scientific and Everyday-KnowledgeConstructs of Reality"" 327 $a""Chapter IV Objectivity as Intersubjectivity:The Interface with Sociology of Knowledge""""Chapter V A Constructivist Sociologyof Knowledge Model""; ""Constructed Reality""; ""Chapter VI Implications for Theological Discourse""; ""1 On the Non-Absolute Character of Theological Speech""; ""2 Human Interaction with a Cognitive Model of God?""; ""3 Ontological Equality of Diverse Designs of Reality as aPrerequisite for Intercontextual Dialogue and Competition""; ""Chapter VII Application of the Model to Early ChristianExamples: The New Reality of the EarlyChristians"" 327 $a""1 The Resurrection of Jesus""""2 The Irrelevance of Worldly Distinctions""; ""3 The a???New Creationa??? of Human Beings""; ""4 The Eucharist""; ""5 New Orientation of Behaviour""; ""6 A Look Back: Jesus of Nazaretha???s Proclamation of Goda???sKingdom in Words and Works""; ""7 Prospects""; ""Chapter VIII Rather intellectus intellectui concordet1than ens intellectui concordat?2 NormativeReflections on the Concept of Truth and onIntercontextual Competition in a PluralisticSociety""; ""1""; ""2""; ""3""; ""4""; ""5""; ""6""; ""Chapter IX The Prospect for a Constructivist Theory ofHistoriography"" 327 $a""1 Emic Constructs: Second-Order Constructs of PastConstructions of Reality""""2 Necessary Additions and Omissions as well as Critical Assessments when Dealing with Historical Sources""; ""3 Etic Constructs of a Second Order: Consciously Deviatingfrom the Understanding of the Past People, Reading theSources a???Against the Graina???""; ""4 The Relationship between Emic and Etic Constructs""; ""5 Historiography as an Integral Part of the Historiana???s Construction of Present Reality""; ""6 Conclusion""; ""AppendixLife after Death in Selected Textsof Ancient Judaism"" 327 $a""1 General Resurrection of the Dead""""2 The Taking up of Righteous Individuals""; ""3 Summary of Jewish Elements of Knowledge from the Time ofEarly Christianity""; ""Selected Bibliography""; ""Index of References""; ""Index of Subjects"" 606 $aKnowledge, Theory of (Religion) 606 $aKnowledge, Theory of, in the Bible 606 $aChristianity$xPhilosophy 606 $aApologetics 615 0$aKnowledge, Theory of (Religion) 615 0$aKnowledge, Theory of, in the Bible. 615 0$aChristianity$xPhilosophy. 615 0$aApologetics. 676 $a231.042 700 $aLampe$b Peter$f1954-$0157145 702 $aBrawley$b Robert L. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910827088603321 996 $aNew Testament theology in a secular world$94006374 997 $aUNINA LEADER 04944nam 22005535 450 001 9910253895003321 005 20250609111212.0 010 $a3-319-33826-9 024 7 $a10.1007/978-3-319-33826-2 035 $a(CKB)3710000000873117 035 $a(DE-He213)978-3-319-33826-2 035 $a(MiAaPQ)EBC4697485 035 $a(PPN)195507665 035 $a(MiAaPQ)EBC6235585 035 $a(EXLCZ)993710000000873117 100 $a20160926d2016 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aValidation of Alternative Methods for Toxicity Testing /$fedited by Chantra Eskes, Maurice Whelan 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (XX, 407 p. 44 illus., 40 illus. in color.) 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v856 311 08$aPrint version: Validation of alternative methods for toxicity testing. [Cham, Switzerland] : Springer, c2016 xx, 407 pages Advances in experimental medicine and biology ; Volume 856. 9783319338248 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aIntroduction -- Validation in support of internationally harmonised OECD Test Guidelines for assessing the safety of chemicals -- Regulatory acceptance of alternative methods in the development and approval of pharmaceuticals -- Validation of alternative in vitro methods to animal testing: concepts, challenges, processes and tools -- Practical aspects of designing and conducting validation studies involving multi-study trials -- Validation of computational methods -- Implementation of New Test Methods into Practical Testing -- Pathway Based Toxicology and Fit-for-Purpose Assays -- Evidence-based toxicology -- Validation of transcriptomics-based in vitro methods -- Ensuring the quality of stem cell-derived in vitro models for toxicity testing -- Validation of bioreactor and human-on-a-chip devices for chemical safety assessment -- Integrated approaches to testing and assessment -- International harmonization and cooperation in the validation of alternative methods -- Evolving the principles and practice of validation for new alternative approaches to toxicity testing. . 330 $aThis book provides information on best practices and new thinking regarding the validation of alternative methods for toxicity testing. It covers the validation of experimental and computational methods and integrated approaches to testing and assessment. Validation strategies are discussed for methods employing the latest technologies such as tissue-on-a-chip systems, stem cells and transcriptomics, and for methods derived from pathway-based concepts in toxicology. Validation of Alternative Methods for Toxicity Testing is divided into two sections, in the first, practical insights are given on the state-of-the-art and on approaches that have resulted in successfully validated and accepted alternative methods. The second section focuses on the evolution of validation principles and practice that are necessary to ensure fit-for-purpose validation that has the greatest impact on international regulatory acceptance of alternative methods. In this context validation needs to keep pace with the considerable scientific advancements being made in toxicology, the availability of sophisticated tools and techniques that can be applied in a variety of ways, and the increasing societal and regulatory demands for better safety assessment. This book will be a useful resource for scientists in the field of toxicology, both from industry and academia, developing new test methods, strategies or techniques, as well as Governmental and regulatory authorities interested in understanding the principles and practicalities of validation of alternative methods for toxicity testing. . 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v856 606 $aPharmaceutical technology 606 $aMolecular biology 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 615 0$aPharmaceutical technology. 615 0$aMolecular biology. 615 14$aPharmaceutical Sciences/Technology. 615 24$aMolecular Medicine. 676 $a615.704028 702 $aEskes$b Chantra$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWhelan$b Maurice$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910253895003321 996 $aValidation of Alternative Methods for Toxicity Testing$92527120 997 $aUNINA LEADER 02019oas 2200793 a 450 001 9910735299003321 005 20260218112215.0 035 $a(DE-599)ZDB2703046-5 035 $a(OCoLC)794005707 035 $a(CONSER) 2012202883 035 $a(CKB)2560000000083811 035 $a(DE-599)2703046-5 035 $a(EXLCZ)992560000000083811 100 $a20120521a20139999 oy a 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aExpert opinion on orphan drugs 210 1$a[London] :$cInforma Healthcare,$d2013- 210 31$a[Abingdon, UK] :$cTaylor & Francis 215 $a1 online resource 300 $aRefereed/Peer-reviewed 311 08$a2167-8707 606 $aRare diseases$vPeriodicals 606 $aOrphan drugs$vPeriodicals 606 $aChemotherapy$vPeriodicals 606 $aOrphan Drug Production 606 $aRare Diseases 606 $aChemotherapy$2fast$3(OCoLC)fst00853595 606 $aOrphan drugs$2fast$3(OCoLC)fst01048416 606 $aRare diseases$2fast$3(OCoLC)fst01090123 608 $aPeriodical. 608 $aPeriodicals.$2fast 615 0$aRare diseases 615 0$aOrphan drugs 615 0$aChemotherapy 615 12$aOrphan Drug Production. 615 22$aRare Diseases. 615 7$aChemotherapy. 615 7$aOrphan drugs. 615 7$aRare diseases. 676 $a615 801 0$bDLC 801 1$bDLC 801 2$bNLM 801 2$bDLC 801 2$bUWW 801 2$bOCLCO 801 2$bOCLCF 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCQ 801 2$bOCLCO 801 2$bCUS 801 2$bOCLCQ 801 2$bTXA 801 2$bDLC 801 2$bAU@ 801 2$bOCLCO 801 2$bOCLCA 801 2$bOCLCQ 801 2$bUEJ 801 2$bOCLCL 906 $aJOURNAL 912 $a9910735299003321 996 $aExpert opinion on orphan drugs$93420082 997 $aUNINA